BillionToOne, Inc.
What does the company do — and does the stock price make sense?

How does the company make money?

BillionToOne develops and sells molecular tests, particularly for prenatal diagnostics and cancer treatment. This review covers the Nasdaq-traded Class A share; the company also has founder shares with greater voting rights.

What supports the business?

First-half revenue rose from 125.536 to 217.836 million USD. Operating results swung from a loss of 3.942 million USD to profit of 23.337 million USD. Growth and a profitable core are therefore established.

What could improve?

More testing, better reimbursement, and growth in oncology diagnostics could significantly expand the business. Returns on the stock depend on whether these advances exceed already high expectations.

How is the stock price assessed?

104.67 USD represents a market capitalization of about 4.94 billion USD before additional option dilution. My midrange growth model yields about 65 USD per share. Good business results alone do not yet make the current price attractive.

What is the main risk?

Reimbursement by payers, competition, and medical evidence affect revenue. Founders participate in control through higher-voting Class B shares; options and stock compensation dilute shareholders. The financing includes additional performance-based payments.

What is the overall assessment?

BillionToOne is growing rapidly with molecular diagnostic tests and is now profitable. At 104.67 USD, a substantial part of future success is already priced in; dilution and financing costs make the valuation more demanding than a view based solely on Class A shares.

Sources used in the analysis

1. Original source 1 · api-v4.fcsapi.com · Oct 21, 2026
2. Original source 2 · www.sec.gov